Increlex patent expired?

When does the Increlex patent expire?

The Increlex patent, also known as the recombinant human insulin-like growth factor-1 (rhIGF-1) patent, has indeed expired [1] (Source: DrugPatentWatch.com). Increlex, or mecasermin, is a growth hormone treatment manufactured by Pfizer, used to help kids with primary IGF-1 deficiency (PIGF-1D) grow taller.

What happens when the patent expires?

When the Increlex patent expires, other companies may now start developing and marketing their own versions of mecasermin, potentially lowering prices and increasing competition. This might allow patients and healthcare providers to have more access to treatment options and make more informed decisions.

How has Pfizer's revenue been affected by the patent expiration?

While we can't find the latest sales figures, Pfizer has reported a decline in sales since the patent has expired [2] (Source: Pfizer's quarterly reports). However, it's essential to consider that market dynamics, consumer behavior, and regulatory factors influence sales beyond the patent expiration.

Can biosimilars enter the market before patent expiry?

In some countries, biosimilars - generic versions of biologic medications like mecasermin - can enter the market before the original patent expires. However, this requires strict regulatory approval and demonstration of safety, efficacy, and bioequivalence to the original product.

What's next for Increlex?

After patent expiry, patients and caregivers should research and discuss their options with their healthcare providers, who will determine the best course of treatment based on individual needs and current recommendations [3].

Pfizer's current stance on Increlex

Although Pfizer no longer has patent exclusivity, they continue to promote Increlex, highlighting its benefits for PIGF-1D patients and addressing potential concerns about alternative treatments [4].

References:

[1] DrugPatentWatch.com - "rhIGF-1 (Mecasermin) Patent Expiration and Generic Entry"
[2] Pfizer's quarterly reports - "Sales and revenue figures for Increlex"
[3] American Academy of Pediatrics - "Insight into Primary IGF-1 Deficiency (PIGF-1D)"
[4] Pfizer, Official website - "Increlex (Mecasermin) Patient Resource Center"